Holen Sie sich die Stockscreener-App
1.46
2.01%
-0.03
Handel nachbörslich:
1.42
-0.04
-2.74%
60 Degrees Pharmaceuticals Inc Aktie (SXTP) Neueste Nachrichten
Top Executive Makes Bold Move With Fresh Buy in Pharma Stock - TipRanks
Insider Buying: Geoffrey Dow Acquires Additional Shares of 60 De - GuruFocus
60 degrees pharmaceuticals CEO buys $10,131 in stock - Investing.com
CEO Geoffrey Dow adds 7,350 SXTP shares in open-market buy - Stock Titan
60 Degrees Pharmaceuticals Licenses Patent to Produce Australian Chestnut Extract - marketscreener.com
Australian chestnut tree targeted for U.S. supplements in 60 Degrees Pharma deal - Stock Titan
60 Degrees Pharmaceuticals (SXTP) proposes 800K-share equity refresh, reverse split - Stock Titan
According to a document submitted to the U.S. Securities and Exchange Commission, the biopharmaceutical company 60 Degrees Pharmaceuticals, Inc. may submit a New Drug Application for its drug tafenoquine to the U.S. Food and Drug Administration bef - Bitget
60 Degrees details tafenoquine priority review voucher strategy - TipRanks
60 Degrees Pharmaceuticals to seek Priority Review Voucher if tafenoquine trial supports NDA - TradingView
60 Degrees Pharmaceuticals (SXTP) details potential NDA and FDA voucher path - Stock Titan
60 Degrees Pharmaceuticals Q1 2026 Earnings: EPS Falls Sharply Short of Estimates as Development Costs MountDebt Analysis Report - The Legal Advocate
SXTP Q1 2026 Earnings: EPS Misses Estimates Amid Pre-Revenue PhaseEarnings Revision Downgrade - newsline.com
SXTP Q1 2026 Earnings: Significant EPS Miss as Company Continues Pre-Revenue PhaseROE Trend Analysis - The Legal Advocate
60 Degrees Pharm 1Q Rev $162,000 >SXTP - Moomoo
60 Degrees Pharmaceuticals (SXTP) Slips 6% as Shares Test Key SupportNew Highs New Lows - newsline.com
60 Degrees Pharmaceuticals enrolls first patient in babesiosis trial - Investing.com
60 Degrees Pharmaceuticals enrolls first patient in babesiosis trial By Investing.com - Investing.com Canada
60 Degrees Pharmaceuticals Announces Early Enrollment of - GlobeNewswire
60 Degrees Pharmaceuticals Inc. (SXTP) Q1 2026 Earnings: EPS Misses Estimates, No Revenue YetFree Cash Flow Trends - The Legal Advocate
60 Degrees Pharma Nears FDA Deadline in Thin Holiday Trading - Bez Kabli
SXTP Q1 2026 Earnings: EPS Misses Estimates by Wide Margin Amid Operational ChallengesBuyback Announcement Report - The Legal Advocate
60 Degrees Pharmaceuticals (SXTP) Holds Near Support After Minor DeclineFlat Correction - Newser
60 Degrees Pharmaceuticals (SXTP) Dips 1.34% as Shares Test Support LevelSupport Level Bounce - Newser
60 Degrees Pharmaceuticals, Inc.Warrant (NQ: SXTPW - The Chronicle-Journal
SXTP Downgraded by HC Wainwright & Co. -- New Rating: Neutral - GuruFocus
60 Degrees Pharm Cut to Neutral From Buy by HC Wainwright & Co. - Moomoo
H.C. Wainwright Downgrades 60 Degrees Pharmaceuticals(SXTP.US) to Hold Rating - Moomoo
60 Degrees Pharmaceuticals (NASDAQ: SXTP) director files initial Form 3 insider report - Stock Titan
60 Degrees Pharmaceuticals appoints Eric Francois to board of directors By Investing.com - Investing.com Nigeria
60 Degrees Pharmaceuticals, Inc. Files Form 8-K with SEC – Company Details, NASDAQ Listing, and Compliance Highlights - Minichart
60 Degrees Pharmaceuticals appoints Eric Francois to board of directors - Investing.com
60 Degrees Pharmaceuticals appoints Eric Francois to board - TradingView
Eric Francois joins 60 Degrees Pharmaceuticals (SXTP) board with deep biotech finance background - Stock Titan
Knight Therapeutics (TSX: GUD) reports exit from SXTP, 0 shares as of Mar 31, 2026 - Stock Titan
60 Degrees Pharmaceuticals, Inc. Q1 2026 Financial Results: Net Loss, Operating Expenses, and Key Financial Highlights - Minichart
CVI/Heights report 7.0% stake in 60 Degrees (NASDAQ: SXTP) - Stock Titan
60 Degrees Pharmaceuticals Releases Q1 2026 Financial Results - AlphaStreet
60 Degrees Pharmaceuticals Announces First Quarter 2026 Results - GlobeNewswire
60 Degrees Pharmaceuticals 1Q 2026: Revenue $162.09K, EPS ($1.28) — 10-Q Summary - TradingView
60 Degrees Pharmaceuticals (NASDAQ: SXTP) posts Q1 2026 loss and flags going concern risk - Stock Titan
MSN Money - MSN
TradingKey - TradingKey
SXTP Stock Price, Quote & Chart | 60 DEGREES PHARMA INC (NASDAQ:SXTP) - ChartMill
60 Degrees reports shared 9.1% stake (SXTP) from warrants and holdings - Stock Titan
SXTP Q1'26 Earnings: EPS estimate is (0.76) USD - TradingView
60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split - ChartMill
The biggest catalyst for 60 Degrees (SXTP) nobody is watching (Momentum Fading) 2026-05-08Ease of Movement - The Legal Advocate
60 Degrees Pharmaceuticals (SXTP) price target decreased by 19.89% to 14.38 - MSN
60 Degrees Pharmaceuticals and Fathom Holdings Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Quantisnow
60 Degrees Pharmaceuticals Inc. (SXTP) upgraded to buy: Here's what you should know - MSN
Analysts Are Bullish on Top Healthcare Stocks: IGC Pharma (IGC), 60 Degrees Pharmaceuticals, Inc. (SXTP) - The Globe and Mail
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):